Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreemen

Heidelberg Pharma AG / Key word(s): AllianceHeidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate13-Jul-2022 / 09:58 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014,...

Related Keywords

Germany ,Japan ,Tokyo ,Frankfurt ,Brandenburg ,Sylvia Wimmer ,Chiome Bioscience ,Heidelberg Pharma Amanitin ,Heidelberg Pharma ,Mc Services ,Agreement For The Development ,Chiome Bioscience Inc ,Frankfurt Stock Exchange ,Heidelberg Pharma Research Gmb ,Distribution Services ,Chiome Bioscience Sign Exclusive ,Target Specific Research ,Option Agreement ,Antibody Drug ,Pharma Research Gmbh ,Heidelberg Pharma Research ,Regulatory Announcements ,Corporate News ,